Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Zynerba Pharmaceuticals, Inc. | a16-6277_1ex99d1.htm |
EX-99.2 - EX-99.2 - Zynerba Pharmaceuticals, Inc. | a16-6277_1ex99d2.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): March 14, 2016
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware |
|
001-37526 |
|
26-0389433 |
(State or Other Jurisdiction of |
|
(Commission |
|
(I.R.S. Employer |
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o |
|
Written communications pursuant to Rule 425 under the Securities Act |
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Item 2.02 Results of Operations and Financial Condition
On March 14, 2016, Zynerba Pharmaceuticals, Inc. (the Company) issued a press release regarding its financial results and operational highlights for the fourth quarter and year ended December 31, 2015. A copy of this press release is furnished as Exhibit 99.1 hereto.
The information in this Item 2.02 (including Exhibit 99.1) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
Item 7.01 Regulation FD Disclosure
On March 14, 2016, the Company released an updated investor presentation to be used in presentations to investors from time to time. A copy of this investor presentation is attached hereto as Exhibit 99.2.
The information in this Item 7.01 (including Exhibit 99.2) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
EXHIBIT |
|
DESCRIPTION |
|
|
|
99.1 |
|
Press Release, dated March 14, 2016. |
99.2 |
|
Zynerba Pharmaceuticals, Inc. Investor Presentation (March 2016) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| ||
|
ZYNERBA PHARMACEUTICALS, INC. | ||
|
| ||
Date: March 14, 2016 |
By: |
/s/ Suzanne Hanlon | |
|
|
Name: |
Suzanne Hanlon |
|
|
Title: |
Secretary, General Counsel and Vice President, Human Resources |